CY1121596T1 - Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα - Google Patents
Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεαInfo
- Publication number
- CY1121596T1 CY1121596T1 CY20191100097T CY191100097T CY1121596T1 CY 1121596 T1 CY1121596 T1 CY 1121596T1 CY 20191100097 T CY20191100097 T CY 20191100097T CY 191100097 T CY191100097 T CY 191100097T CY 1121596 T1 CY1121596 T1 CY 1121596T1
- Authority
- CY
- Cyprus
- Prior art keywords
- benzoxazinone
- amids
- salt
- formula
- endothelial
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical compound C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 title 1
- 230000001054 cortical effect Effects 0.000 title 1
- 230000003511 endothelial effect Effects 0.000 abstract 2
- -1 benzoxazinone amide Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Αποκαλύπτονται ορισμένα παράγωγα αμιδίων βενζοξαζινόνης χημικού τύπου (I), ή φαρμακευτικά αποδεκτά άλατα αυτών, (Χημικού Τύπου (I)) που δρουν ως αλατοκορτικοειδείς (MR) ρυθμιστές υποδοχέα που μπορούν μειώσουν το οξειδωτικό στρες στο ενδοθήλιο και συνεπώς βελτιώνουν την αγγειακή λειτουργία, με μεθόδους για τη πιθανή θεραπευτική χρήση τους, με φαρμακευτικές συνθέσεις που τα περιέχουν και με διεργασίες για την προετοιμασία τέτοιων ενώσεων.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462018790P | 2014-06-30 | 2014-06-30 | |
| PCT/GB2015/051860 WO2016001631A1 (en) | 2014-06-30 | 2015-06-26 | Benzoxazinone amides as mineralocorticoid receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121596T1 true CY1121596T1 (el) | 2020-05-29 |
Family
ID=53539739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100097T CY1121596T1 (el) | 2014-06-30 | 2019-01-24 | Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10017502B2 (el) |
| EP (1) | EP3160948B1 (el) |
| JP (1) | JP6368383B2 (el) |
| KR (1) | KR102012222B1 (el) |
| CN (1) | CN106536491B (el) |
| AR (1) | AR101036A1 (el) |
| AU (1) | AU2015282450C1 (el) |
| CA (1) | CA2953655C (el) |
| CY (1) | CY1121596T1 (el) |
| DK (1) | DK3160948T3 (el) |
| EA (1) | EA029518B1 (el) |
| ES (1) | ES2707726T3 (el) |
| HR (1) | HRP20190147T1 (el) |
| HU (1) | HUE042370T2 (el) |
| LT (1) | LT3160948T (el) |
| ME (1) | ME03316B (el) |
| MX (1) | MX367404B (el) |
| PL (1) | PL3160948T3 (el) |
| PT (1) | PT3160948T (el) |
| RS (1) | RS58274B1 (el) |
| SI (1) | SI3160948T1 (el) |
| SM (1) | SMT201900039T1 (el) |
| TR (1) | TR201900659T4 (el) |
| TW (1) | TWI677498B (el) |
| UY (1) | UY36195A (el) |
| WO (1) | WO2016001631A1 (el) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3160948T3 (pl) * | 2014-06-30 | 2019-04-30 | Astrazeneca Ab | Amidy benzoksazynonu jako modulatory receptorów mineralokortykoidowych |
| CA3105626A1 (en) | 2018-07-19 | 2020-01-23 | Astrazeneca Ab | Methods of treating hfpef employing dapagliflozin and compositions comprising the same |
| CN112107568B (zh) * | 2019-06-19 | 2022-03-25 | 北京龙嘉博创医药科技有限公司 | 二芳基酰胺类化合物及其应用 |
| JOP20200098A1 (ar) | 2019-08-30 | 2021-02-28 | Astrazeneca Ab | طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين |
| TW202220672A (zh) | 2020-07-27 | 2022-06-01 | 瑞典商阿斯特捷利康公司 | 用達格列淨治療慢性腎臟病之方法 |
| AU2022292685A1 (en) * | 2021-06-15 | 2024-01-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Benzoxazinone derivatives |
| TW202409023A (zh) | 2022-07-14 | 2024-03-01 | 美商富曼西公司 | 除草苯并𠯤 |
| WO2024047574A1 (en) | 2022-09-01 | 2024-03-07 | Astrazeneca Ab | Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases |
| WO2024125591A1 (zh) * | 2022-12-15 | 2024-06-20 | 正大天晴药业集团股份有限公司 | 苯并恶嗪酮类化合物的结晶及其制备 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004528335A (ja) * | 2001-04-23 | 2004-09-16 | アストラゼネカ アクチボラグ | 血管新生の治療に使用のベンゾオキサジノン誘導体 |
| CA2510851A1 (en) * | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
| MX2007000449A (es) * | 2004-07-14 | 2007-03-28 | Ligand Pharm Inc | Compuestos moduladores de receptor intracelular y metodos. |
| KR20070046150A (ko) * | 2004-07-28 | 2007-05-02 | 아이알엠 엘엘씨 | 스테로이드 호르몬 핵 수용체의 조절제로서의 화합물 및조성물 |
| JP2009523701A (ja) | 2005-12-28 | 2009-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| TWI385161B (zh) | 2006-02-02 | 2013-02-11 | Mitsubishi Tanabe Pharma Corp | 含氮雜雙環化合物 |
| SI2089367T1 (sl) | 2006-10-31 | 2012-02-29 | Pfizer Prod Inc | Spojine pirazolina kot antagonisti mineralokortikoidnih receptorjev |
| DE102007009494A1 (de) | 2007-02-27 | 2008-08-28 | Bayer Healthcare Ag | Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung |
| JP2010522168A (ja) | 2007-03-23 | 2010-07-01 | メルク・シャープ・エンド・ドーム・コーポレイション | 鉱質コルチコイドレセプターモジュレータ |
| JP5363312B2 (ja) | 2007-04-09 | 2013-12-11 | 第一三共株式会社 | ピロール誘導体のアトロプ異性体 |
| JP5173653B2 (ja) * | 2007-08-01 | 2013-04-03 | 田辺三菱製薬株式会社 | 医薬組成物 |
| US8258131B2 (en) | 2007-08-01 | 2012-09-04 | Mitsubishi Tanabe Pharma Corporation | Fused bicyclic compound |
| PE20091057A1 (es) | 2007-12-19 | 2009-07-20 | Lilly Co Eli | Antagonistas del receptor mineralcorticoide y metodos de uso |
| UY31905A (es) * | 2008-06-18 | 2010-01-29 | Astrazeneca Ab | Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones. |
| US20100094000A1 (en) | 2008-09-03 | 2010-04-15 | Takeda Pharmaceutical Company Limited | Pyrazole compounds |
| WO2010098286A1 (ja) | 2009-02-25 | 2010-09-02 | 第一三共株式会社 | ミネラルコルチコイド受容体拮抗薬を含有する医薬 |
| EA019179B1 (ru) | 2009-03-12 | 2014-01-30 | Эли Лилли Энд Компани | Антагонист минералокортикоидного рецептора и способы его применения |
| JP2012523405A (ja) | 2009-04-10 | 2012-10-04 | ファイザー・インク | ４，５−ジヒドロ−１ｈ−ピラゾール化合物およびその薬学的使用 |
| EP2569310A1 (en) | 2010-05-11 | 2013-03-20 | Pfizer Inc | Morpholine compounds as mineralocorticoid receptor antagonists |
| US8979337B2 (en) | 2010-05-11 | 2015-03-17 | Koninklijke Philips N.V. | Lighting module |
| JPWO2012008435A1 (ja) | 2010-07-13 | 2013-09-09 | 大日本住友製薬株式会社 | ビアリールアミド誘導体またはその薬理学的に許容される塩 |
| JP2013542255A (ja) | 2010-11-10 | 2013-11-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ミネラルコルチコイド受容体アンタゴニストとしてのピリジル尿素 |
| PL3160948T3 (pl) * | 2014-06-30 | 2019-04-30 | Astrazeneca Ab | Amidy benzoksazynonu jako modulatory receptorów mineralokortykoidowych |
-
2015
- 2015-06-26 PL PL15736015T patent/PL3160948T3/pl unknown
- 2015-06-26 ME MEP-2019-19A patent/ME03316B/me unknown
- 2015-06-26 CN CN201580035032.8A patent/CN106536491B/zh active Active
- 2015-06-26 AU AU2015282450A patent/AU2015282450C1/en active Active
- 2015-06-26 DK DK15736015.7T patent/DK3160948T3/en active
- 2015-06-26 UY UY0001036195A patent/UY36195A/es not_active Application Discontinuation
- 2015-06-26 TR TR2019/00659T patent/TR201900659T4/tr unknown
- 2015-06-26 US US15/320,379 patent/US10017502B2/en active Active
- 2015-06-26 SI SI201530572T patent/SI3160948T1/sl unknown
- 2015-06-26 ES ES15736015T patent/ES2707726T3/es active Active
- 2015-06-26 EP EP15736015.7A patent/EP3160948B1/en active Active
- 2015-06-26 KR KR1020177002518A patent/KR102012222B1/ko active Active
- 2015-06-26 MX MX2017000183A patent/MX367404B/es active IP Right Grant
- 2015-06-26 HU HUE15736015A patent/HUE042370T2/hu unknown
- 2015-06-26 PT PT15736015T patent/PT3160948T/pt unknown
- 2015-06-26 WO PCT/GB2015/051860 patent/WO2016001631A1/en active Application Filing
- 2015-06-26 CA CA2953655A patent/CA2953655C/en active Active
- 2015-06-26 RS RS20190085A patent/RS58274B1/sr unknown
- 2015-06-26 EA EA201790046A patent/EA029518B1/ru not_active IP Right Cessation
- 2015-06-26 SM SM20190039T patent/SMT201900039T1/it unknown
- 2015-06-26 JP JP2016575499A patent/JP6368383B2/ja active Active
- 2015-06-26 LT LTEP15736015.7T patent/LT3160948T/lt unknown
- 2015-06-29 TW TW104120998A patent/TWI677498B/zh active
- 2015-06-29 US US14/753,239 patent/US9394291B2/en active Active
- 2015-06-30 AR ARP150102098A patent/AR101036A1/es active IP Right Grant
-
2019
- 2019-01-22 HR HRP20190147TT patent/HRP20190147T1/hr unknown
- 2019-01-24 CY CY20191100097T patent/CY1121596T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121596T1 (el) | Αμιδια βενζοξαζινονης ως αλατοκορτικοειδεις ρυθμιστες υποδοχεα | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1124548T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου | |
| CY1121418T1 (el) | Παρεμποδιστες ιου ηπατιτιδας c | |
| MX377124B (es) | Compuestos heterociclicos y usos de los mismos. | |
| EA201791256A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| MX379110B (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| MX376833B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| MX382122B (es) | Oxiesteroles y metodos de uso de los mismos. | |
| CY1120340T1 (el) | Gpr40 ρυθμιστες πυρρολιδινης για τη θεραπεια ασθενειων οπως διαβητη | |
| CY1121746T1 (el) | Αναστολεις mgat2 τετραζολονο-υποκατεστημενης διυδροπυριδινονης | |
| CY1124059T1 (el) | Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| CY1123576T1 (el) | Συμπυκνωμενα παραγωγα θειοφαινιου χρησιμα ως αναστολεις του napi-iib | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
| JOP20190050A1 (ar) | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي | |
| CY1122321T1 (el) | Παραγωγα φθοροϊνδολιου ως θετικοι αλλοστερικοι διαμορφωτες του μουσκαρινικου υποδοχεα μ1 | |
| EA201791600A1 (ru) | Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора | |
| CY1122381T1 (el) | Παραγωγα ιμιδαζοπυριδαζινης ως αναστολεις pi3kbhta | |
| NI201600091A (es) | UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS | |
| EA201990723A1 (ru) | Кристаллические формы | |
| MX2016014118A (es) | Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes. | |
| CY1123185T1 (el) | Παραγωγα ινδολιου |